Background & objectives: Studies have shown that immunohistochemical (IHC) staining using epidermal growth factor receptor (EGFR) mutation specific antibodies, is an easy and cost-effective, screening method compared with molecular techniques. The purpose of present study was to assess the percentage positivity of IHC using EGFR mutation specific antibodies in lung biopsy samples from patients with primary lung adenocarcinoma (ADC). Methods: Two hundred and six biopsies of primary lung ADC were subjected to EGFR mutation specific antibodies against del E746-A750 and L858R. Detection of EGFR mutation done by high resolution melting analysis (HRM) was used as gold standard. A concordance was established between molecular and IHC results. ...
Epidermal growth factor receptor (EGFR) is a novel target for therapy in subsets of non-small cell l...
Epidermal growth factor receptor (EGFR) is a novel target for therapy in subsets of non-small cell l...
Background:Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) p...
Background & objectives: Studies have shown that immunohistochemical (IHC) staining using epider...
Background: The recent development of antibodies specific for the major hotspot mutations in the epi...
Aim We assessed the diagnostic accuracy of epidermal growth factor receptor (EGFR) mutant-specific a...
BACKGROUND: Epidermal growth factor receptor (EGFR) mutation status is the most valuable indicator i...
Background and objective Patients with non-small cell lung cancer (NSCLC) harboring mutations of the...
EGFR mutations are the best predictors of response to EGFR kinase inhibitors in lung adenocarcinoma....
Aims Identification of epidermal growth factor receptor (EGFR) mutations in lung adenocarcinomas is ...
Epidermal growth factor receptor (EGFR) mutation status is the most valuable indicator in the screen...
In recent years, it has been well known that non-small cell lung cancer (NSCLC) patients with mutati...
Background: Epidermal growth factor receptor (EGFR) is a novel target for therapy in a subset of non...
BACKGROUND: Various studies have assessed the diagnostic accuracy of EGFR mutation-specific antibodi...
Various studies have assessed the diagnostic accuracy of EGFR mutation-specific antibodies in non-sm...
Epidermal growth factor receptor (EGFR) is a novel target for therapy in subsets of non-small cell l...
Epidermal growth factor receptor (EGFR) is a novel target for therapy in subsets of non-small cell l...
Background:Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) p...
Background & objectives: Studies have shown that immunohistochemical (IHC) staining using epider...
Background: The recent development of antibodies specific for the major hotspot mutations in the epi...
Aim We assessed the diagnostic accuracy of epidermal growth factor receptor (EGFR) mutant-specific a...
BACKGROUND: Epidermal growth factor receptor (EGFR) mutation status is the most valuable indicator i...
Background and objective Patients with non-small cell lung cancer (NSCLC) harboring mutations of the...
EGFR mutations are the best predictors of response to EGFR kinase inhibitors in lung adenocarcinoma....
Aims Identification of epidermal growth factor receptor (EGFR) mutations in lung adenocarcinomas is ...
Epidermal growth factor receptor (EGFR) mutation status is the most valuable indicator in the screen...
In recent years, it has been well known that non-small cell lung cancer (NSCLC) patients with mutati...
Background: Epidermal growth factor receptor (EGFR) is a novel target for therapy in a subset of non...
BACKGROUND: Various studies have assessed the diagnostic accuracy of EGFR mutation-specific antibodi...
Various studies have assessed the diagnostic accuracy of EGFR mutation-specific antibodies in non-sm...
Epidermal growth factor receptor (EGFR) is a novel target for therapy in subsets of non-small cell l...
Epidermal growth factor receptor (EGFR) is a novel target for therapy in subsets of non-small cell l...
Background:Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) p...